United Therapeutics Corp. | Ownership
Companies that own United Therapeutics Corp.
BlackRock Fund Advisors
4,301,615
9.86%
9,065
0.03%
06/30/2018
The Vanguard Group, Inc.
3,677,173
8.44%
115,007
0.02%
06/30/2018
Fidelity Management & Research Co.
3,445,468
7.91%
-343,166
0.04%
06/30/2018
AQR Capital Management LLC
2,091,908
4.8%
269,437
0.23%
06/30/2018
SSgA Funds Management, Inc.
1,994,004
4.58%
-100,423
0.02%
06/30/2018
Palo Alto Investors LP
1,625,234
3.73%
2,603
7.69%
06/30/2018
Renaissance Technologies LLC
1,556,200
3.57%
22,322
0.2%
06/30/2018
Acadian Asset Management LLC
1,145,014
2.63%
-77,149
0.36%
06/30/2018
Dimensional Fund Advisors LP
990,685
2.27%
32,611
0.03%
06/30/2018
Goldman Sachs & Co. LLC (Private Banking)
862,262
1.98%
-65,762
0.06%
06/30/2018
| Address |
1040 Spring Street
Silver Spring Maryland 20910
United States
|
|
Employees
|
- |
| Website |
http://www.unither.com |
| Updated |
07/08/2019 |
| United Therapeutics Corp. biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. |
